Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)-
- CAS No.
- 2396465-33-9
- Chemical Name:
- Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)-
- Synonyms
- GCN2-IN-7;Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)-
- CBNumber:
- CB212199024
- Molecular Formula:
- C22H23BrN8OS
- Molecular Weight:
- 527.44
- MDL Number:
- MOL File:
- 2396465-33-9.mol
- MSDS File:
- SDS
Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0613281 | GCN2-IN-7 99.92% | 2396465-33-9 | 1mg | $406 | 2026-06-04 | Buy |
| ChemScene | CS-0613281 | GCN2-IN-7 99.92% | 2396465-33-9 | 5mg | $1023 | 2026-06-04 | Buy |
| ChemScene | CS-0613281 | GCN2-IN-7 99.92% | 2396465-33-9 | 10mg | $1625 | 2026-06-04 | Buy |
| ChemScene | CS-0613281 | GCN2-IN-7 99.92% | 2396465-33-9 | 25mg | $2769 | 2026-06-04 | Buy |
| ChemScene | CS-0613281 | GCN2-IN-7 99.92% | 2396465-33-9 | 50mg | $3614 | 2026-06-04 | Buy |
Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)- Chemical Properties, Uses, Production
Uses
GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC50=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo[1].
in vivo
GCN2-IN-7 (oral gavage; 15 mg/kg; BID; 17 d) shows robust target engagement in vivo at a reasonable dose[1].
GCN2-IN-7 (oral gavage; 50 mg/kg; BID; 17 d) inhibits tumor growth in vivo of the LL2 syngeneic mouse tumor model[1].
| Animal Model: | Balb/c mice injected with RENCA cells[1] |
| Dosage: | 15 mg/kg |
| Administration: | Oral gavage; 15 mg/kg; BID; 17 days |
| Result: | Showed robust target engagement of GCN2 in both tumor (average of 84%) and spleen (average of 80%) tissues. Showed an average of 65% reduction of downstream marker Activation Transcription Factor 4 (ATF4) in compound-treated mice compared to the vehicle treatment group. |
| Animal Model: | LL2 syngeneic mouse model[1] |
| Dosage: | 50 mg/kg |
| Administration: | Oral gavage; 50 mg/kg; BID; 17 days |
| Result: | Showed tumor growth inhibition (56%) after 26 days of dosing compared to the vehicle group. |
References
[1] Jackson JJ, et al. Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy. J Med Chem. 2022 Sep 20. DOI:10.1021/acs.jmedchem.2c00736
Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)- Preparation Products And Raw materials
Raw materials
Preparation Products
Cyclopentanecarboxamide, 3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethyl-, (1R,3R)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Shanghai Pengque Chemical Technology Co., LTD | 15317013857 15901926503 | pengque01@sina.com | China | 977 | 58 |
| Nantong Hi-Future Biotechnology Co., Ltd | +86-0513; 18051384581 | sales@chemhifuture.com | China | 3075 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd. | 025-66061636 19370895928 | qqyang@aikonchem.com | China | 9995 | 58 |
| Shanghai Amole Biotechnology Co., Ltd. | 13370042665 18916960931 | 2596183085@qq.com | China | 17234 | 58 |





